heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
== Function == The corticotropin-releasing hormone receptor binds corticotropin-releasing hormone, a potent mediator of endocrine, autonomic, behavioral, and immune responses to stress. CRF1 receptors in mice mediate ethanol enhancement of GABAergic synaptic transmission.
=== Michael: All American D-Bag === Michael, who calls himself an all-American badass, picked on William because of his culture and hobbies. It is unknown why this episode has never aired in America. However, it has aired on the Fox8 channel of Foxtel and Austar in Australia. It has never been leaked on the internet, and is not available on the Bully Beatdown website. A preview can be seen at the end of Andy's episode. Michael tapped out five times in the first round and was knocked out with a stomach blow in the second. William won $10,000 and an apology from his bully.
More cardiovascular work from the same research group followed, including a proposal that megadoses of vitamin E could slow down and even reverse the development of atherosclerosis. Subsequent research showed no association between vitamin E supplementation and cardiovascular events such as nonfatal stroke or myocardial infarction, or cardiovascular mortality. There is a long history of belief that topical application of vitamin E containing oil benefits burn and wound healing. This belief persists even though scientific reviews refuted this claim. The role of vitamin E in infant nutrition has a long research history. From 1949 onward there were trials with premature infants suggesting that oral alpha-tocopherol was protective against edema, intracranial hemorrhage, hemolytic anemia and retrolental fibroplasia. A more recent review concluded that vitamin E supplementation in preterm infants reduced the risk of intracranial hemorrhage and retinopathy, but noted an increased risk of sepsis.
For services to the Meat Industry. Kenneth Adams-Morgan. For Political Service. Ronald Morgan, Deputy Governor and Head of Custody, Her Majesty's Prison Noranside. Richard William Morley, lately Catering Manager, Ring & Brymer (City). For services to the Catering Industry. Kathnne Amanda Morris, Clerk to the Corporation, East Birmingham College. For services to Education. Donald Fergusson Morrison, District Registrar, Strachur, Argyll. For services to the community. Mane Morrow. For services to disabled people. Walter Kenneth John Mummery, lately Principal Prison Officer, Her Majesty's Prison and Young Offenders' Institution Moorland. Joan F. Munro, Speech and Language Therapy Manager, Highland Communities NHS Trust. For services to Health Care. Robert Nathaniel Murray. For services to the community in Derby. The Reverend Canon James Robert Musgrave. For services to the community. Samuel Newgarth. For services to Music and for charitable services in Dorset. Jeanne Marjorie Nicholls, President, Cornwall and Isles of Scilly Leagues of Hospital and Community Friends. For services to Health Care. David Edgar Thomas Nichols, Senior Scientific Officer, the Defence Evaluation and Research Agency, Ministry of Defence. Mary Nimmons. For services to Health Care. The Reverend Canon Richard Henry Norburn. For services to the community in Bury St Edmunds, Suffolk. Doreen Norgrove. For services to the community in Farnham, Surrey. Sheila Norman, Chairman, Royal Life Saving Society, Suffolk Branch, and Commonwealth Development Liaison Officer, Royal Life Saving Society UK.
== Education == Foyer attended Portsmouth Polytechnic (now the University of Portsmouth) from 1971–74, achieving a BSc with Class II, Division I Honours in Biology (CNAA). From 1974–77 she attended the Department of Biochemistry, King's College London, where she completed her PhD. During this time Foyer also attended a course on immunology at Chelsea College, London. In 1998 Foyer was elected a Fellow of the Institute of Biology.
Sources: en.wikipedia.org
The president of the Republic of the Union of Myanmar (Burmese: နိုင်ငံတော်သမ္မတ, MLCTS: nuing ngam tau samma.ta., lit. 'President of the State') is the head of state and head of government of Myanmar. The president chairs the National Defence and Security Council and leads the Union Government (Cabinet), the executive branch of the Myanmar government. The presidency was established in 1948, when Burma gained its independence from the British Empire. During this period, the president was the ceremonial head of state while prime minister is the actual head of government. The presidency was abolished following the 1962 coup d'etat, when Ne Win assumed the powers of both head of state and head of government as the Chairman of the Revolutionary Council and the Revolutionary Government. The 1974 Constitution reintroduced the presidency, to be held by the Chairman of the Council of State. The 1988 coup d'etat again led to the presidency's abolishment, with the Chairman of the State Law and Order Restoration Council (reconstituted in 1997 as the State Peace and Development Council) assuming the functions of the head of state. The 2008 Constitution introduced a presidential system, where the president is both the head of state and government. Thein Sein assumed the presidency in 2011. After the 2015 election, the extraconstitutional post of State Counsellor of Myanmar was created for Aung San Suu Kyi, the leader of the majority party, the National League for Democracy, because she was ineligible for the presidency.
==== Economic gains ==== In 2014, the aquaculture produced fish overtook wild caught fish, in supply for human food. This means there is a huge demand for vaccines, in prevention of diseases. The reported annual loss fish, calculates to >10 billion USD. This is from approximately 10% of all fishes dying from infectious diseases. The high annual losses increases the demand for vaccines. Even though there are about 24 traditionally used vaccines, there is still demand for more vaccines. The breakthrough of DNA-vaccines has sunk the cost of vaccines. The alternative to vaccines would be antibiotics and chemotherapy, which are more expensive and with bigger drawbacks. DNA-vaccines have become the most cost-efficient method of preventing infectious diseases. This bodes well for DNA-vaccines becoming the new standard both in fish vaccines, and in general vaccines.
Napoleon took the reserve of the Army of the North, and reunited his forces with those of Ney to pursue Wellington's army, after he ordered Marshal Grouchy to take the right wing of the Army of the North and stop the Prussians regrouping. In the first of a series of miscalculations, both Grouchy and Napoleon failed to realise that the Prussian forces were already reorganised and were assembling at the city of Wavre. The French army did nothing to stop a rather leisurely retreat that took place throughout the night and into the early morning by the Prussians. As the 4th, 1st, and 2nd Prussian Corps marched through the town towards Waterloo, the 3rd Prussian Corps took up blocking positions across the river, and although Grouchy engaged and defeated the Prussian rearguard under the command of Lt-Gen von Thielmann in the Battle of Wavre (18–19 June) it was 12 hours too late. In the end, 17,000 Prussians had kept 33,000 badly needed French reinforcements off the field. Napoleon delayed the start of fighting at the Battle of Waterloo on the morning of 18 June for several hours while he waited for the ground to dry after the previous night's rain. By late afternoon, the French army had not succeeded in driving Wellington's forces from the escarpment on which they stood. When the Prussians arrived and attacked the French right flank in ever-increasing numbers, Napoleon's strategy of keeping the coalition armies divided had failed and a combined coalition general advance drove his army from the field in confusion.
25499Es + 4820Ca → 302119Uue* → no atoms It is highly unlikely that this reaction will be able to create any atoms of ununennium in the near future, given the extremely difficult task of making sufficient amounts of einsteinium-254, which is favoured for production of ultraheavy elements because of its large mass, relatively long half-life of 270 days, and availability in significant amounts of several micrograms, to make a large enough target to increase the sensitivity of the experiment to the required level; einsteinium has not been found in nature and has only been produced in laboratories, and in quantities smaller than those needed for effective synthesis of superheavy elements. However, given that ununennium is only the first period 8 element on the extended periodic table, it may well be discovered in the near future through other reactions, and indeed an attempt to synthesise it is currently ongoing in Japan. Currently, none of the period 8 elements has been discovered yet, and it is also possible, due to drip instabilities, that only the lower period 8 elements, up to around element 128, are physically possible. No attempts at synthesis have been made for any heavier alkali metals: due to their extremely high atomic number, they would require new, more powerful methods and technology to make.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.